<DOC>
	<DOCNO>NCT02954796</DOCNO>
	<brief_summary>This study test safety drug call SGN-CD352A , find side effect . SGN-CD352A give every 4 week small group patient multiple myeloma .</brief_summary>
	<brief_title>A Safety Study SGN-CD352A Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>The study 2 part . In first part , different dose SGN-CD352A give different patient ( individual patient get dose treatment ) . The dos low start trial , increase low dose level prove safe . In second part study , 2 dose level safe show promising activity MM give patient</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Diagnosis MM require systemic therapy ( per International Myeloma Working Group [ IMWG ] ) . Age 18 year old . An Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Life expectancy great month . Received least 2 prior line therapy MM include immunomodulatory drug proteasome inhibitor . Measurable disease , define least one following : Serum M protein 0.5 g/dL high , Urine M protein 200 mg/24 hr high , Abnormal serum free light chain ( SFLC ) ratio . Adequate hematologic , renal , hepatic function A negative pregnancy test ( female childbearing potential ) . Patients must provide write informed consent . Other invasive malignancy within past 3 year . Active cerebral/meningeal disease relate underlying malignancy . Active Grade 3 high infection . Known positive HIV know active hepatitis B C. Previous allogeneic stem cell transplant . Idiopathic interstitial pneumonia impaired diffusion capacity lung carbon monoxide ( DLCO ) . Cerebrovascular cardiovascular event , congestive heart failure within last 6 month . Females pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>